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Hospital-acquired pneumonia and ventilator-associated pneumonia (HAP/VAP) occur in 5 to \> 20 cases per 1000 hospital admissions and 2--16 episodes per 1000 ventilator days, respectively \[[@CR1]\]. Methicillin-sensitive and methicillin-resistant *Staphylococcus aureu*s (*S. aureus*; MSSA and MRSA) are important disease-causing pathogens in HAP/VAP \[[@CR2], [@CR3]\]. In 2016, the Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) recommended vancomycin or linezolid in patients with HAP/VAP when empiric coverage of MRSA is indicated \[[@CR3]\], despite some evidence of reduced susceptibility to vancomycin in MRSA and MSSA isolates \[[@CR4]\]. Rising MRSA vancomycin minimum inhibitory concentration (MIC) values are not universal, and vancomycin-intermediate *S. aureus* (VISA) remains uncommon \[[@CR3]\]. However, *S. aureus* strains with vancomycin MIC 1--2 µg/mL---considered vancomycin-susceptible---may harbor vancomycin-intermediate subpopulations, and heterogeneous VISA (hVISA) prevalence among *S. aureus* isolates increased significantly from 0.4% in 2009 to 1.2% in 2011 in the US \[[@CR5]\]. Furthermore, MRSA infections with organisms with vancomycin MIC ≥ 1.5 µg/mL (excluding documented hVISA) are significantly associated with treatment failure \[[@CR4]\]. Linezolid is not bactericidal against staphylococci and is not suitable for all patients due to drug interactions and hematologic effects \[[@CR6]\]. Ceftobiprole is approved in the UK and other countries for treatment of HAP but is not indicated for VAP and not available in the US \[[@CR7], [@CR8]\]. Alternative treatment options are needed for patients with HAP/VAP caused by *S. aureus* with high vancomycin MICs and patients unable to tolerate vancomycin or linezolid.

Telavancin is a rapidly acting bactericidal lipoglycopeptide antibiotic with a dual mechanism of action, including inhibition of bacterial cell wall biosynthesis and disruption of cell membrane function \[[@CR9]\]. In the US, telavancin is approved in adults for treatment of complicated skin and skin structure infections due to susceptible Gram-positive pathogens. In addition, telavancin is approved for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) when alternative treatments are not suitable \[[@CR10]\]. In a post hoc analysis, telavancin demonstrated comparable efficacy to vancomycin in a limited number of patients with HABP/VABP with concurrent *S. aureus* bacteremia \[[@CR11]\]. Telavancin provides clinical outcomes that are noninferior to vancomycin in treatment of patients with HABP due to both MSSA and MRSA \[[@CR2]\]. This post hoc analysis of the Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia (ATTAIN) trials \[[@CR2]\] assesses a subset of microbiologically evaluable patients with hospital-acquired baseline monomicrobial *S. aureus* respiratory infections with vancomycin MIC ≥ 1.0 µg/mL.
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Methods and results from the identical, randomized, double-blind, comparator-controlled, parallel-group phase 3 ATTAIN trials (NCT00107952 and NCT00124020) were reported previously \[[@CR2]\]. Briefly, adult patients who developed pneumonia after 48 h of inpatient care or \< 7 days after discharge were eligible; patients who received other potentially effective therapy for \> 24 h before randomization had only Gram-negative bacteria on Gram stain or culture, or had other pulmonary disease precluding evaluation of therapeutic response were excluded \[[@CR2]\]. Patients were randomized to receive intravenous telavancin 10 mg/kg every 24 h or vancomycin 1 g intravenously every 12 h for 7--21 days; the vancomycin regimen could be monitored and adjusted according to the institutional policy at each site but had to be performed such that blinding was not compromised \[[@CR2]\]. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Clinical assessments were performed at baseline and daily throughout study treatment, at end of therapy, and at follow-up/test-of-cure visits \[[@CR2]\]. Modified Acute Physiology and Chronic Health Evaluation (APACHE II) was performed at baseline; missing score components were imputed as 0. Efficacy endpoints were proportions of clinical cure, defined as lack of progression or improvement in radiographic findings at end of treatment and resolution of signs and symptoms of pneumonia at follow-up or test-of-cure visits \[[@CR2]\], and all-cause 28-day mortality, measured as Kaplan--Meier survival estimate at day 28 based on reported deaths. Safety was assessed from adverse events (AEs); renal safety was determined by rate of decline in renal function, defined as creatinine clearance (CrCl) shift from baseline by two or more categories (\< 30, 30--50, \> 50--80, and \> 80 mL/min) during therapy \[[@CR12]\]. Creatinine clearance was calculated by Cockcroft--Gault using the smaller of ideal or actual body weight.

This post hoc subgroup analysis assessed microbiologically evaluable patients from ATTAIN with monomicrobial respiratory infections caused by *S. aureus* with vancomycin MIC ≥ 1.0 μg/mL. Vancomycin MIC was determined from broth microdilution methods; identification of hVISA was not performed prospectively. Patients who were protocol-adherent or died from HAP on or after study day 3 and had a Gram-positive respiratory pathogen recovered from baseline respiratory specimens or blood cultures were considered microbiologically evaluable \[[@CR2]\] and included. Efficacy and safety analyses included all randomized microbiologically evaluable patients receiving ≥ 1 dose of study medication. Subgroup analyses of clinical cure were performed by patient age (≥ 65 years vs. \< 65 years), VAP diagnosis, APACHE II score (≥ 20 vs. \< 20), and pathogen (MSSA vs. MRSA). Differences in proportion were calculated using a 95% Wald confidence interval (CI) adjusted via the Agresti--Caffo method. No formal hypothesis testing was performed. Treatment-emergent AEs (TEAEs) were summarized by preferred term and system organ class.
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Of 1503 patients treated in ATTAIN, 194 microbiologically evaluable patients had monomicrobial respiratory *S. aureus* infections with vancomycin MIC ≥ 1.0 μg/mL; 89 patients were treated with telavancin, and 105 with vancomycin. Demographics and baseline characteristics were comparable in telavancin- and vancomycin-treated patients (Table [1](#Tab1){ref-type="table"}). The majority of patients were ≥ 65 years of age, male, and white (Table [1](#Tab1){ref-type="table"}). At baseline, 24.2% of patients had VAP, 76.8% had MRSA, and the proportion of patients with MRSA was numerically lower among those treated with telavancin versus vancomycin (Table [1](#Tab1){ref-type="table"}). The most common comorbidities among telavancin- and vancomycin-treated patients were hypertension (62.9%), anemia (37.6%), diabetes mellitus (35.6%), chronic obstructive airway disease (26.8%), atrial fibrillation (24.2%), and congestive cardiac failure (18.6%); proportions of patients with renal comorbidities were comparable between treatment arms (Table [1](#Tab1){ref-type="table"}).Table 1Baseline demographics of microbiologically evaluable patients with monomicrobial *Staphylococcus aureus* infection with vancomycin minimum inhibitory concentration ≥ 1.0 µg/mLCharacteristicTelavancin (*n* = 89)Vancomycin (*n* = 105)Age (years) Mean (SD)61.7 (18.6)67.0 (15.4) Median (IQR)67.0 (50.0, 75.0)72.0 (60.0, 77.0)Age distribution, *n* (%) \< 65 years40 (44.9)37 (35.2) ≥ 65 years49 (55.1)68 (64.8)Sex, *n* (%) Male47 (52.8)61 (58.1) Female42 (47.2)44 (41.9)Ethnicity, *n* (%) Hispanic or latino20 (22.5)21 (20.0) Not hispanic or latino69 (77.5)84 (80.0)Race, *n* (%) American Indian or Alaska Native5 (5.6)3 (2.9) Asian17 (19.1)20 (19.0) Black or African American3 (3.4)4 (3.8) White64 (71.9)78 (74.3)BMI (kg/m^2^) Mean (SD)26.2 (5.84)25.5 (6.03) Median (IQR)25.4 (22.2, 29.1)23.8 (21.6, 28.3)APACHE II Score (mean, SD) Mean (SD)15.2 (6.09)15.5 (6.95) Median (IQR)15.0 (11.0, 19.0)14.0 (11.0, 20.0)CrCl (mL/min) Mean (SD)89.7 (62.2)76.0 (57.4) Median (IQR)68.5 (43.0, 118.5)63.6 (40.7, 91.7)VAP, *n* (%) Yes26 (29.2)21 (20.0) No63 (70.8)84 (80.0)MRSA, *n* (%) Yes61 (68.5)88 (83.8) No28 (31.5)17 (16.2)MSSA, *n* (%) Yes28 (31.5)17 (16.2) No61 (68.5)88 (83.8)Common comorbidities (≥ 20%), *n* (%) Hypertension55 (61.8)67 (63.8) Anemia39 (43.8)34 (32.4) Diabetes mellitus35 (39.3)34 (32.4) Atrial fibrillation22 (24.7)25 (23.8) Cardiac failure, congestive22 (24.7)14 (13.3) Chronic obstructive airways disease21 (23.6)31 (29.5)Renal comorbidities Renal failure, acute9 (10.1)12 (11.4) Renal failure, chronic9 (10.1)9 (8.6) Renal insufficiency4 (4.5)5 (4.8) Renal impairment1 (1.1)0 Blood creatinine increased1 (1.1)0As treatment allocation was randomized, no statistical comparison of baseline characteristics was performed*APACHE II* Acute Physiology and Chronic Health Evaluation II,*BMI* body mass index,*CrCl* creatinine clearance,*IQR* interquartile range,*MRSA* methicillin-resistant *Staphylococcus aureus*,*MSSA* methicillin-sensitive *Staphylococcus aureus*,*SD* standard deviation,*VAP* ventilator-acquired pneumonia

The overall clinical cure rate for telavancin treatment was 76/89 (85.4%) versus 78/105 (74.3%) for vancomycin treatment \[treatment difference (95% CI), 11.1% (− 0.002%, 22.2%)\]. Clinical cure rates were numerically greater for telavancin relative to vancomycin treatment in patients ≥ 65 years of age \[40/49 (81.6%) vs. 45/68 (66.2%); treatment difference (95% CI), 15.5% (− 0.9%, 30.2%)\], although similar in patients aged \< 65 years \[36/40 (90.0%) and 33/37 (89.2%); treatment difference (95% CI), 0.8% (− 13.4%, 15.3%)\] (Fig. [1](#Fig1){ref-type="fig"}). Telavancin treatment also produced numerically greater clinical cure rates relative to vancomycin in patients with VAP \[24/26 (92.3%) vs. 10/21 (47.6%); treatment difference (95% CI), 44.7% (18.1%, 64.9%)\], but similar cure rates in patients without VAP \[52/63 (82.5%) and 68/84 (81.0%); treatment difference (95% CI), 1.6% (− 11.0%, 14.2%\]) (Fig. [1](#Fig1){ref-type="fig"}). Patients in subgroups defined by APACHE II score had numerically greater cure rates for telavancin relative to vancomycin treatment \[APACHE II score ≥ 20, 15/21 (71.4%) vs. 15/27 (55.6%); treatment difference (95% CI), 15.9% (− 11.7%, 40.5%); APACHE II score \< 20, 61/68 \[(9.7%) vs. 63/78 (80.8%); treatment difference (95% CI), 8.9% (− 2.9%, 20.1%)\] (Fig. [1](#Fig1){ref-type="fig"}). Clinical cure rates were numerically higher for telavancin relative to vancomycin treatment for patients with both MSSA \[25/28 (89.3%) vs. 12/17 (70.6%); treatment difference (95% CI), 18.7% (− 5.9%, 42.4%)\] and MRSA \[51/61 (83.6%) vs. 66/88 (75.0%); treatment difference (95% CI), 8.6% (− 4.4%, 21.6%)\] (Fig. [1](#Fig1){ref-type="fig"}). The 28-day all-cause mortality proportion was 85.2% survival in telavancin-treated patients versus 80.2% survival in vancomycin-treated patients \[treatment difference (95% CI), 5.0% (− 5.8%, 15.8%)\].Fig. 1Difference (telavancin--vancomycin) in clinical cure rates at test of cure with associated 95% confidence intervals in microbiologically evaluable patients. *APACHE II* Acute Physiology and Chronic Health Evaluation II, *MRSA* methicillin-resistant *Staphylococcus aureus*,*MSSA* methicillin-sensitive *Staphylococcus aureus*,*TLV* telavancin,*VAN* vancomycin,*VAP* ventilator-associated pneumonia

The most common TEAEs were diarrhea \[telavancin 10/89 (11.2%); vancomycin 19/105 (18.1%)\], anemia \[telavancin 10/89 (11.2%); vancomycin 15/105 (14.3%)\], hypokalemia \[telavancin 4/89 (4.5%); vancomycin 14/105 (13.3%)\], and decubitus ulcer \[telavancin 5/89 (5.6%); vancomycin, 13/105 (12.4%)\]. A total of 7 (7.9%) patients receiving telavancin and 6 patients (5.7%) receiving vancomycin had renal function decline by a shift from baseline of ≥ 2 CrCl categories. Over 90% of the patients (181/194) had no shift in renal function.
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This analysis assessed the efficacy and safety of telavancin versus vancomycin in microbiologically evaluable ATTAIN patients with monomicrobial *S. aureus* respiratory infection. Clinical cure and 28-day mortality rates were numerically favorable in patients treated with telavancin versus vancomycin. Clinical cure rates were numerically greater in elderly (≥ 65 years of age) patients; patients with VAP; and, to a lesser degree, patients with APACHE II score ≥ 20 treated with telavancin relative to vancomycin. Changes in renal function and incidence and types of AEs were comparable between patients receiving telavancin and vancomycin.

Despite concerns about vancomycin MIC and treatment failure \[[@CR4]\], 2016 IDSA/ATS treatment guidelines---based on seven randomized trials including ATTAIN---recommend vancomycin or linezolid for empiric coverage of MRSA in patients with HAP/VAP \[[@CR3]\]. Clinical outcomes in ATTAIN were comparable for telavancin or vancomycin treatment with the exception of a trend toward greater all-cause mortality in patients with CrCl \< 30 mL/min treated with telavancin versus vancomycin \[[@CR2], [@CR13]\]. In this post hoc analysis of ATTAIN, telavancin had at least comparable efficacy relative to vancomycin in patients with monomicrobial *S. aureus* HAP/VAP caused by both MSSA and MRSA with vancomycin MIC ≥ 1 μg/mL; clinical cure rates for patients treated with telavancin versus vancomycin were similar to those for all patients with monomicrobial *S. aureus* in ATTAIN \[[@CR2]\]. The small number of patients prevented meaningful subgroup analysis of patients with reduced renal function. Telavancin could potentially be useful for treatment coverage of MRSA in patients with HAP/VAP acquired in facilities with organisms with high vancomycin MICs.

Vancomycin dosing in this study was 1 g every 12 h, but could be monitored and adjusted according to the institutional policy per site, and dosing to trough levels was allowed. In the ATTAIN studies, 66% of patients had mean vancomycin trough concentrations ≥ 10 µg/mL. Although the 2016 IDSA guidelines recommend a target trough concentration of 15--20 µg/mL for treatment of HAP with risk of MRSA \[[@CR2], [@CR3]\], another post hoc analysis revealed that ATTAIN patients with vancomycin trough levels ≥ 15 µg/mL had a higher incidence of renal AEs without improvement in clinical cure rate relative to those with lower trough levels \[[@CR14]\]. Appropriate vancomycin dosing for optimized efficacy and safety remains a challenge. The study is limited by its post hoc nature, small patient numbers---particularly in subgroup analyses---and lack of significance testing. However, clinical cure rates were comparable or greater in patients with HAP/VAP caused by *S. aureus* with vancomycin MIC ≥ 1 µg/mL treated with telavancin relative to vancomycin. Patient age, VAP diagnosis, and baseline APACHE II score may inform decisions regarding using telavancin versus vancomycin in this population, as the numerically favorable clinical cure rates for elderly patients, patients with VAP, and patients with baseline APACHE II score ≥ 20 treated with telavancin versus vancomycin suggest a benefit of telavancin treatment in such patients. Dedicated studies with larger populations of patients meeting these criteria could clarify any possible advantages of telavancin relative to other treatment options.

Conclusions {#Sec5}
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In settings where organisms with vancomycin MIC ≥ 1 μg/mL are prevalent, telavancin is an alternative to vancomycin for empiric or specific coverage of MRSA in patients with HAP/VAP. The potential benefits of telavancin versus vancomycin must be balanced with possible increased risks for decline in renal function and trends for increased mortality in patients with pre-existing renal impairment.
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